CDD Spotlight Interview with James Moe – President, CEO and a Co-Founder of Oligomerix ACS Annual Meeting 2015
Oligomerix Raises Series B Round to Mount New Attack on Alzheimer’s Brian Gormley, Dow Jones Venture Wire, May 22, 2013
Targeting Tau For Alzheimer’s Disease and Related Neurodegenerative Disorders. Dr. Eliot J. Davidowitz and Dr. James G. Moe. Drug Discovery World, Fall 2012
Tau Gains Popularity as Alzheimer’s Drug Target Brian Orelli, BioWorld® Insight, July 2, 2012, Vol. 20, no. 27.
Oligomerix Targets Tau Protein to Tackle Alzheimer’s Disease Catherine Shaffer, BioWorld® Today, February 8, 2012, Vol. 23, no. 26.
Oligomerix Tau Tapping BioCentury, December 15, 2008